Reply to H. Seibert et al

Abstract

Seibert et al 1 note perceived concerns in the recent report by Bailey et al 2 demonstrating additional clinical validation of the 31-gene expression profile (31-GEP) in a large, unselected cohort of patients tested with the 31-GEP and showing that patients tested with the 31-GEP have lower overall and melanoma-specific mortality risk relative to untested patients.